These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 10537964

  • 1. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.
    Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G.
    Pharmacoeconomics; 1999 May; 15(5):469-80. PubMed ID: 10537964
    [Abstract] [Full Text] [Related]

  • 2. [Economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France].
    Le Pen C, Lilliu H, Allicar MP, Olivier V, Gregor KJ.
    Encephale; 1999 May; 25(4):281-6. PubMed ID: 10546082
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V, Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine.
    JAMA; 2003 Nov 26; 290(20):2693-702. PubMed ID: 14645311
    [Abstract] [Full Text] [Related]

  • 4. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N, Foster RH, Olney R, Plosker GL.
    Drugs; 2001 Nov 26; 61(1):111-61. PubMed ID: 11217867
    [Abstract] [Full Text] [Related]

  • 5. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.
    Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A.
    Pharmacoeconomics; 2000 Dec 26; 18(6):567-79. PubMed ID: 11227395
    [Abstract] [Full Text] [Related]

  • 6. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH, Goa KL.
    Pharmacoeconomics; 1999 Jun 26; 15(6):611-40. PubMed ID: 10538333
    [Abstract] [Full Text] [Related]

  • 7. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.
    Glazer WM, Johnstone BM.
    J Clin Psychiatry; 1997 Jun 26; 58 Suppl 10():50-4. PubMed ID: 9265917
    [Abstract] [Full Text] [Related]

  • 8. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
    Almond S, O'Donnell O.
    Pharmacoeconomics; 2000 Apr 26; 17(4):383-9. PubMed ID: 10947493
    [Abstract] [Full Text] [Related]

  • 9. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.
    Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley CM.
    Qual Life Res; 1999 Aug 26; 8(5):417-26. PubMed ID: 10474283
    [Abstract] [Full Text] [Related]

  • 10. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample.
    Hamilton SH, Edgell ET, Revicki DA, Breier A.
    Int Clin Psychopharmacol; 2000 Sep 26; 15(5):245-55. PubMed ID: 10993126
    [Abstract] [Full Text] [Related]

  • 11. A cost-effectiveness clinical decision analysis model for schizophrenia.
    Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE.
    Am J Manag Care; 1998 Mar 26; 4(3):345-55. PubMed ID: 10178497
    [Abstract] [Full Text] [Related]

  • 12. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
    Kinon BJ, Roychowdhury SM, Milton DR, Hill AL.
    J Clin Psychiatry; 2001 Mar 26; 62 Suppl 2():17-21. PubMed ID: 11232746
    [Abstract] [Full Text] [Related]

  • 13. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
    Gomez JC, Crawford AM.
    J Clin Psychiatry; 2001 Mar 26; 62 Suppl 2():6-11. PubMed ID: 11232753
    [Abstract] [Full Text] [Related]

  • 14. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.
    Wright P, Meehan K, Birkett M, Lindborg SR, Taylor CC, Morris P, Breier A.
    Clin Ther; 2003 May 26; 25(5):1420-8. PubMed ID: 12867218
    [Abstract] [Full Text] [Related]

  • 15. [Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia++ in Spain].
    Sacristán JA, Gómez JC, Salvador-Carulla L.
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1997 May 26; 25(4):225-34. PubMed ID: 9412161
    [Abstract] [Full Text] [Related]

  • 16. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.
    Gureje O, Miles W, Keks N, Grainger D, Lambert T, McGrath J, Tran P, Catts S, Fraser A, Hustig H, Andersen S, Crawford AM.
    Schizophr Res; 2003 Jun 01; 61(2-3):303-14. PubMed ID: 12729882
    [Abstract] [Full Text] [Related]

  • 17. Olanzapine versus haloperidol treatment in first-episode psychosis.
    Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C, Tollefson GD.
    Am J Psychiatry; 1999 Jan 01; 156(1):79-87. PubMed ID: 9892301
    [Abstract] [Full Text] [Related]

  • 18. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia.
    Tunis SL, Johnstone BM, Gibson PJ, Loosbrock DL, Dulisse BK.
    J Clin Psychiatry; 1999 Jan 01; 60 Suppl 19():38-45; discussion 46. PubMed ID: 10507279
    [Abstract] [Full Text] [Related]

  • 19. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.
    Hamilton SH, Revicki DA, Genduso LA, Beasley CM.
    Neuropsychopharmacology; 1998 Jan 01; 18(1):41-9. PubMed ID: 9408917
    [Abstract] [Full Text] [Related]

  • 20. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
    Tollefson GD, Sanger TM.
    Am J Psychiatry; 1997 Apr 01; 154(4):466-74. PubMed ID: 9090332
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.